2. Search Result
Search Result
Results for "

SF3b1

" in MedChemExpress (MCE) Product Catalog:

15

Inhibitors & Agonists

1

Antibodies

4

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-16399
    Pladienolide B
    5 Publications Verification

    		 Apoptosis SF3B1 Cancer
    Pladienolide B is a potent cancer cell growth inhibitor that targets the SF3B1 subunit of the spliceosome. Pladienolide B exerts antitumor activities mediated through the inhibition of pre-mRNA splicing. Pladienolide B induces apoptosis .
    Pladienolide B
  • HY-16466
    Spliceostatin A

    		SF3B1 Cancer
    Spliceostatin A, the FR901464 (HY-16212) methylated derivative, is a potent anti-tumor agent. Spliceostatin A inhibits splicing and promotes pre-mRNA accumulation by binding SF3B1. SF3B1 is a subcomplex of U2 small nuclear ribonucleoprotein in the spliceosome. Spliceostatin A induces Apoptosis in chronic lymphocytic leukemia (CLL) cells .
    Spliceostatin A
  • HY-111517
    H3B-8800

    		Apoptosis SF3B1 Cancer
    H3B-8800 is a potent and orally active SF3B splicing modulator. H3B-8800 direct interaction with the SF3b complex and shows anti-cancer activity. H3B-8800 has the potential for the research of acute myeloid leukemia (AML) with SF3B1 mutant .
    H3B-8800
  • HY-168534
    WX-02-23

    		SF3B1 Apoptosis Cancer
    WX-02-23 is a small-molecule probe that stereoselectively and site-specifically binds to C258 of FOXA1 and C1111 of SF3B1. WX-02-23 remodels FOXA1's chromatin binding and pioneer activity in a DNA-dependent manner, disrupts spliceosome assembly, and enhances the thermal stability of SF3B1. WX-02-23 inhibits tumor cell proliferation and induces apoptosis. WX-02-23 can be used for research on cancers such as prostate cancer .
    WX-02-23
  • HY-141881
    PROTAC-O4I2

    		PROTACs Apoptosis SF3B1 Cancer
    PROTAC-O4I2 is a PROTAC targets splicing factor 3B1 (SF3B1). PROTAC-O4I2 induces FLAG-SF3B1 degradation with an IC50 value of 0.244 μM in K562 cells. PROTAC-O4I2 also induces cellular apoptosis in K562 WT cells .
    PROTAC-O4I2
  • HY-162386
    UM4118

    		Cuproptosis Mitochondrial Metabolism Cancer
    UM4118 is a potent copper-selective non-genotoxic copper ionophore that induces cuproptosis in acute myeloid leukemia cells. UM4118 exhibits stronger activity against SF3B1G12C mutant acute myeloid leukemia cells. UM4118 transports extracellular copper into cells, elevates intracellular and mitochondrial copper levels, and triggers lipoylated DLAT aggregation, proteotoxic stress, iron-sulfur cluster protein depletion, reduced lipoylated protein levels, and maximal mitochondrial respiratory damage. UM4118 cytotoxicity can be enhanced by supplementation with extracellular copper, abolished by copper chelation, and shows synthetic lethal effects in the absence of iron-sulfur cluster biosynthesis/transport genes. UM4118 can be used for the study of acute myeloid leukemia .
    UM4118
  • HY-158783
    SACLAC

    		Ceramidase Bcl-2 Family LPL Receptor Apoptosis Neurological Disease
    SACLAC, a Ceramide analog, is a potent and covalent acid ceramidase (ASAH1; AC) inhibitor with a Ki of 97.1 nM. SACLAC effectively blocks AC activity and induces a decrease in sphingosine 1-phosphate (S1P) and total ceramide levels. SACLAC reduces the levels of splicing factor SF3B1 and alternative Mcl-1 mRNA splicing, increases pro-apoptotic Mcl-1S levels to induce apoptosis in acute myeloid leukemia (AML) cells. SACLAC reduces the leukemic burden in human AML xenograft mouse models .
    SACLAC
  • HY-RS12760
    SF3B1 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    SF3B1 Human Pre-designed siRNA Set A contains three designed siRNAs for SF3B1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    SF3B1 Human Pre-designed siRNA Set A
    SF3B1 Human Pre-designed siRNA Set A
  • HY-RS17082
    Sf3b1 Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Sf3b1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Sf3b1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Sf3b1 Mouse Pre-designed siRNA Set A
    Sf3b1 Mouse Pre-designed siRNA Set A
  • HY-RS23526
    Sf3b1 Rat Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Sf3b1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Sf3b1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Sf3b1 Rat Pre-designed siRNA Set A
    Sf3b1 Rat Pre-designed siRNA Set A
  • HY-122637
    Sudemycin K

    		SF3B1 Cancer
    Sudemycin K is a selective splicing inhibitor targeting SF3B1. Sudemycin K blocks U2 snRNP recognition of branch point sequences in pre-mRNA, inducing tumor-specific splicing deregulation and apoptosis. Sudemycin K is promising for research of SF3B1-mutated malignancies such as chronic lymphocytic leukemia (CLL) and myelodysplastic syndromes (MDS) .
    Sudemycin K
  • HY-120907
    Sudemycin E

    		SF3B1 Cancer
    Sudemycin E is an analog of FR901464 (HY-16212). Sudemycin E can induce reversible changes in alternative splicing and abnormalities in chromatin modifications by binding to SF3B1, a component of the U2 small nuclear ribonucleoprotein (snRNP), thereby leading to the death of cancer cells. Sudemycin E has anti-tumor activity and can be used in tumor research .
    Sudemycin E
  • HY-181421
    WX-02-43

    		SF3B1 Cancer
    WX-02-43 is a weak covalent inhibitor of SF3B1, and is the (1S,3R) enantiomer of WX-02-23 (HY-168534). WX-02-43 cannot effectively covalently modify the C258 site in the DNA-binding domain of FOXA1, and its inhibitory activity against SF3B1 is also weaker than that of WX-02-23. WX-02-43 serves as a negative control probe that fails to remodel the chromatin binding pattern and transcriptional activity of FOXA1. WX-02-43 can be used in studies on cancers such as prostate cancer to verify the specific effects of WX-02-23 on FOXA1 and SF3B1 targets .
    WX-02-43
  • HY-15867
    Meayamycin B

    (+)-Meayamycin B

    		 SF3B1 Bcl-2 Family Apoptosis Cancer
    Meayamycin B ((+)-Meayamycin B) is a potent SF3B1 inhibitor. Meayamycin B upregulates the proapoptotic Mcl-1S and downregulates Mcl-1L at the pre-mRNA splicing level. Meayamycin B does not regulate the alternative splicing of Bcl-x. Meayamycin B and ABT-737 (HY-50907) synergistically causes Apoptosis. Meayamycin B exhibits anticancer activity against non-small cell lung cancer .
    Meayamycin B
  • HY-RS12761
    SF3B2 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    SF3B2 Human Pre-designed siRNA Set A contains three designed siRNAs for SF3B2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    SF3B2 Human Pre-designed siRNA Set A
    SF3B2 Human Pre-designed siRNA Set A

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: